Beam Therapeutics Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Beam Therapeutics Inc. (BEAM) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.52 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-05-07
- Beam Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $1.52M.
- Beam Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $3.11M, a 39.92% decline year-over-year.
- Beam Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $352.00K, a 40.80% increase year-over-year.
- Beam Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $5.17M, a 193.75% increase year-over-year.
- Beam Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $3.85M, a 90.62% decline from fiscal 2022.
- Beam Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $41.05M, a 58.34% increase from fiscal 2021.
- Beam Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $25.93M, a 65.31% decline from fiscal 2020.
- Beam Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $74.72M, a 1101.14% increase from fiscal 2019.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-03-31 | $1.52M 10-Q · filed 2024-05-07 | $4.63M derived: sum of 2 quarters · filed 2024-05-07 | $4.98M derived: sum of 3 quarters · filed 2024-05-07 | |
| 2023-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.46M derived: sum of 2 quarters · filed 2024-02-27 | $3.85M 10-K · filed 2024-02-27 | |
| 2023-09-30 | $352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $744.00K 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $392.00K 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $5.42M derived: sum of 2 quarters · filed 2024-02-27 | $36.23M derived: sum of 3 quarters · filed 2024-02-27 | $41.05M 10-K · filed 2024-02-27 |
| 2022-09-30 | $250.00K 10-Q · filed 2022-11-07 | $31.05M derived: sum of 2 quarters · filed 2022-11-07 | $35.88M 10-Q · filed 2023-11-08 | $37.64M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $30.80M 10-Q · filed 2022-08-09 | $35.63M 10-Q · filed 2023-08-08 | $37.39M derived: sum of 3 quarters · filed 2024-02-27 | $37.39M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $4.82M 10-Q · filed 2023-05-10 | $6.58M derived: sum of 2 quarters · filed 2024-02-27 | $6.58M derived: sum of 3 quarters · filed 2024-02-27 | $7.38M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.76M derived: sum of 2 quarters · filed 2024-02-27 | $2.56M derived: sum of 3 quarters · filed 2024-02-27 | $25.93M 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $798.00K derived: sum of 2 quarters · filed 2022-11-07 | $24.16M 10-Q · filed 2022-11-07 | $93.09M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $798.00K 10-Q · filed 2022-08-09 | $24.16M 10-Q · filed 2022-08-09 | $93.09M derived: sum of 3 quarters · filed 2023-02-28 | $93.09M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $23.37M 10-Q · filed 2022-05-09 | $92.29M derived: sum of 2 quarters · filed 2023-02-28 | $92.29M derived: sum of 3 quarters · filed 2023-02-28 | $94.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $68.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $68.93M derived: sum of 2 quarters · filed 2023-02-28 | $70.69M derived: sum of 3 quarters · filed 2023-02-28 | $74.72M 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $1.76M derived: sum of 2 quarters · filed 2021-11-08 | $5.79M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $1.76M 10-Q · filed 2021-08-10 | $5.79M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $4.03M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $6.22M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |